GAIT
What is GAIT (Gut-Brain Axis Integrating Technology)?
The results of our research on central nervous system disorders related to AGEs have shown significant parallels with the recently globally recognized Gut-Brain Axis Theory, particularly in terms of the onset mechanisms. Recognizing this, we have understood that by applying our Microbiome Screening System, we can offer solutions for the treatment of neurodegenerative diseases. GAIT (Gut-brain Axis Integrating Technology) is our unique core technology that preserves the brain's integrity, which can be compromised by AGEs or harmful bacteria, thus preventing and providing a groundbreaking approach to the treatment of diseases such as Parkinson's and Alzheimer's.Causal Link of AGEs to the Gut-Brain (GB) Axis
We initiated research on factors related to the Gut-Brain Axis among the candidate causes of Alzheimer's, which is the most common and severe degenerative brain disorder, similar to Parkinson's disease. Through this, we independently completed a pathological physiological map and sought to explore treatment options based on this foundation.We have deduced that the generation of AGEs through the precursor reactions of glycotoxins traversing the Gut-Brain Axis affects brain cells and the Blood-Brain Barrier (BBB), leading to numerous vicious cycles in the processes of generating key biomarkers of Alzheimer's, such as tau protein and beta-amyloid.
Effect of MCT501 in Parkinson’s Induction Model
The effect of MCT501 was evaluated in a Parkinson's disease animal model induced by PM (Proteus Mirabilis) strain administration, confirming the recovery rate of motor function according to the dosage of MCT501. Results showed that compared to the group not receiving MCT501, the group receiving it exhibited restored motor function, as depicted in the graph. These findings confirmed that MCT501 has dose-dependent improvement efficacy for Parkinson's disease.
